胃癌的治疗性免疫调节
Therapeutic Immunomodulation of Gastric Cancer
DOI: 10.12677/jcpm.2024.32046, PDF,   
作者: 邓莉莉*：青海大学研究生院，青海 西宁；沈存芳#：青海大学附属医院肿瘤内科，青海 西宁
关键词: 胃癌；免疫治疗；免疫检查点抑制剂；PD-1；PD-L1；CTLA-4；治疗；生物标志物；Gastric Cancer； Immunotherapy； Immune Checkpoint Inhibitors； PD-1； PD-L1； CTLA-4； Treatment； Biomarkers
摘要: 胃癌是一种消化系统恶性肿瘤，是世界第六大最常见的癌症，也是与肿瘤疾病死亡的第二大原因。免疫治疗药物的出现和发展为胃癌患者带来了显著的生存优势，同时也对传统药物治疗模式提出了挑战。近年来，特别是免疫检查点抑制剂作为一种新兴的治疗方式，它通过阻断特定的信号通路，特别是CTLA4通路和PD-1/PD-L1通路发挥作用。本文主要概述了晚期GC免疫治疗的最新进展，包括免疫检查点抑制剂、癌症疫苗、血管内皮生长因子-A抑制剂和嵌合抗原受体T细胞治疗。
Abstract: Gastric cancer, a malignant tumor of the digestive system, is the sixth most common cancer in the world and the second leading cause of death associated with oncological disease. The emergence and development of immunotherapy drugs have brought significant survival advantages to gastric cancer patients, but also challenged the traditional drug treatment model. In recent years, immune checkpoint inhibitors in particular have emerged as an emerging therapeutic modus operandi, which work by blocking specific signaling pathways, especially the CTLA4 pathway and the PD-1/PD-L1 pathway. This article mainly reviews the recent advances in advanced GC immunotherapy, including immune checkpoint inhibitors, cancer vaccines, vascular endothelial growth factor-A inhibitors, and chimeric antigen receptor T cell therapy.
文章引用：邓莉莉, 沈存芳. 胃癌的治疗性免疫调节[J]. 临床个性化医学, 2024, 3(2): 315-322. https://doi.org/10.12677/jcpm.2024.32046

参考文献

[1] Zhao, L., Liu, Y., Zhang, S., Wei, L., Cheng, H., Wang, J. and Wang, J. (2022) Impacts and Mechanisms of Metabolic Reprogramming of Tumor Microenvironment for Immunotherapy in Gastric Cancer. Cell Death & Disease, 13, Article No. 378. [Google Scholar] [CrossRef] [PubMed]
[2] Kindlund, B., Sjoling, A., Yakkala, C., Adamsson, J., Janzon, A., Hansson, L.E., Hermansson, M., Janson, P., Winqvist, O. and Lundin, S.B. (2017) CD4 Regulatory T Cells in Gastric Cancer Mucosa Are Proliferating and Express High Levels of IL-10 but Little TGF-β. Gastric Cancer, 20, 116-125. [Google Scholar] [CrossRef] [PubMed]
[3] Negura, I., Pavel-Tanasa, M. and Danciu, M. (2023) Regulatory T Cells in Gastric Cancer: Key Controllers from Pathogenesis to Therapy. Cancer Treatment Reviews, 120, Article 102629. [Google Scholar] [CrossRef] [PubMed]
[4] Akkanapally, V., Bai, X.F. and Basu, S. (2024) Therapeutic Immunomodulation in Gastric Cancer. Cancers, 16, Article 560. [Google Scholar] [CrossRef] [PubMed]
[5] Jin, X., Liu, Z., Yang, D., Yin, K. and Chang, X. (2022) Recent Progress and Future Perspectives of Immunotherapy in Advanced Gastric Cancer. Frontiers in Immunology, 13, Article 948647. [Google Scholar] [CrossRef] [PubMed]
[6] Abdel-Rahman, O. (2016) Immune Checkpoints Aberrations and Gastric Cancer; Assessment of Prognostic Value and Evaluation of Therapeutic Potentials. Critical Reviews in Oncology/Hematology, 97, 65-71. [Google Scholar] [CrossRef] [PubMed]
[7] Wilke, H., Muro, K., Van Cutsem, E., Oh, S.C., Bodoky, G., Shimada, Y., Hironaka, S., Sugimoto, N., Lipatov, O., Kim, T.Y., et al. (2014) Ramucirumab Plus Paclitaxel versus Placebo Plus Paclitaxel in Patients with Previously Treated Advanced Gastric or Gastro-Oesophageal Junction Adenocarcinoma (RAINBOW): A Double-Blind, Randomised Phase 3 Trial. The Lancet Oncology, 15, 1224-1235. [Google Scholar] [CrossRef] 
[8] Solomon, B.L. and Garrido-Laguna, I. (2018) Upper Gastrointestinal Malignancies in 2017, Current Perspectives and Future Approaches. Future Oncology, 14, 947-962. [Google Scholar] [CrossRef] [PubMed]
[9] Kang, Y.K., Boku, N., Satoh, T., Ryu, M.H., Chao, Y., Kato, K., Chung, H.C., Chen, J.S., Muro, K., Kang, W.K., et al. (2017) Nivolumab in Patients with Advanced Gastric or Gastro-Oesophageal Junction Cancer Refractory to, or Intolerant of, at Least Two Previous Chemotherapy Regimens (ONO-4538-12, ATTRACTION-2): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial. The Lancet, 390, 2461-2471. [Google Scholar] [CrossRef] 
[10] Yang, L., Wang, Y. and Wang, H. (2019) Use of Immunotherapy in the Treatment of Gastric Cancer. Oncology Letters, 18, 5681-5690. [Google Scholar] [CrossRef] [PubMed]
[11] Bang, Y.J., Golan, T., Dahan, L., Fu, S., Moreno, V., Park, K., Geva, R., De Braud, F., Wainberg, Z.A., Reck, M., et al. (2020) Ramucirumab and Durvalumab for Previously Treated, Advanced Non-Small-Cell Lung Cancer, Gastric/Gastro-Oesophageal Junction Adenocarcinoma, or Hepatocellular Carcinoma: An Open-Label, Phase Ia/b Study (JVDJ). European Journal of Cancer, 137, 272-284. [Google Scholar] [CrossRef] [PubMed]
[12] Moehler, M., Dvorkin, M., Boku, N., Ozguroglu, M., Ryu, M.H., Muntean, A.S., Lonardi, S., Nechaeva, M., Bragagnoli, A.C., Coskun, H.S., et al. (2021) Phase III Trial of Avelumab Maintenance after First-Line Induction Chemotherapy versus Continuation of Chemotherapy in Patients with Gastric Cancers: Results from JAVELIN Gastric 100. Journal of Clinical Oncology, 39, 966-977. [Google Scholar] [CrossRef] 
[13] Moehler, M.H., Kato, K., Arkenau, H.-T., Oh, D.-Y., Tabernero, J., Cruz-Correa, M., Wang, H., Xu, H., Li, J., Yang, S., et al. (2023) Rationale 305, Phase 3 Study of Tislelizumab Plus Chemotherapy vs Placebo Plus Chemotherapy as First-Line Treatment (1L) of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (GC/GEJC). Journal of Clinical Oncology, 41, 286. [Google Scholar] [CrossRef] 
[14] Zayac, A. and Almhanna, K. (2020) Esophageal, Gastric Cancer and Immunotherapy: Small Steps in the Right Direction? Translational Gastroenterology and Hepatology, 5, Article 9. [Google Scholar] [CrossRef] [PubMed]
[15] Moslehi, J.J., et al. (2018) Increased Reporting of Fatal Immune Checkpoint Inhibitor-Associated Myocarditis. The Lancet, 391, 933. [Google Scholar] [CrossRef] 
[16] Mahmood, S.S., et al. (2018) Myocarditis in Patients Treated with Immune Checkpoint Inhibitors. Journal of the American College of Cardiology, 71, 1755-1764. [Google Scholar] [CrossRef] [PubMed]
[17] Cortazar, F.B., et al. (2020) Clinical Features and Outcomes of Immune Checkpoint Inhibitor-Associated AKI: A Multicenter Study. Journal of the American Society of Nephrology, 31, 435-446. [Google Scholar] [CrossRef] 
[18] Davis, E.J., et al. (2019) Hematologic Complications of Immune Checkpoint Inhibitors. Oncologist, 24, 584-588. [Google Scholar] [CrossRef] [PubMed]
[19] Sato, H., Okonogi, N. and Nakano, T. (2020) Rationale of Combination of Anti-PD-1/PD-L1 Antibody Therapy and Radiotherapy for Cancer Treatment. International Journal of Clinical Oncology, 25, 801-809. [Google Scholar] [CrossRef] [PubMed]
[20] Togashi, Y., Shitara, K. and Nishikawa, H. (2019) Regulatory T Cells in Cancer Immunosuppression—Implications for Anticancer Therapy. Nature Reviews Clinical Oncology, 16, 356-371. [Google Scholar] [CrossRef] [PubMed]
[21] Rocha, S., Basto, A.P., Ijsselsteijn, M.E., Teles, S.P., Azevedo, M.M., Gonçalves, G., et al. (2021) Immunophenotype of Gastric Tumors Unveils a Pleiotropic Role of Regulatory T Cells in Tumor Development. Cancers, 13, Article 421. [Google Scholar] [CrossRef] [PubMed]
[22] Bębnowska, D., Grywalska, E., Niedźwiedzka-Rystwej, P., Sosnowska-Pasiarska, B., Smok-Kalwat, J., Pasiarski, M., Góźdź, S., Roliński, J. and Polkowski, W. (2020) CAR-T Cell Therapy—An Overview of Targets in Gastric Cancer. Journal of Clinical Medicine, 9, Article 1894. [Google Scholar] [CrossRef] [PubMed]
[23] Caruso, H.G., Heimberger, A.B. and Cooper, L.J.N. (2019) Steering CAR T Cells to Distinguish Friend from Foe. Oncoimmunology, 8, e1271857. [Google Scholar] [CrossRef] 
[24] Sun, F., Yu, X., Ju, R., Wang, Z. and Wang, Y. (2022) Antitumor Responses in Gastric Cancer by Targeting B7H3 via Chimeric Antigen Receptor T Cells. Cancer Cell International, 22, Article No. 50. [Google Scholar] [CrossRef] [PubMed]
[25] Li, H., Huang, H., Zhang, T., Feng, H., Wang, S., Zhang, Y., Ji, X., Cheng, X. and Zhao, R. (2022) Apatinib: A Novel Antiangiogenic Drug in Monotherapy or Combination Immunotherapy for Digestive System Malignancies. Frontiers in Immunology, 13, Article 937307. [Google Scholar] [CrossRef] [PubMed]
[26] Zeng, Z., Yang, B. and Liao, Z. (2021) Progress and Prospects of Immune Checkpoint Inhibitors in Advanced Gastric Cancer. Future Oncology, 17, 1553-1569. [Google Scholar] [CrossRef] [PubMed]
[27] Wang, M., Huang, Y., Kong, J.C., Sun, Y., Tantalo, D.G., Yeang, H.X.A., Ying, L., Yan, F., Xu, D., Halse, H., et al. (2020) High-Dimensional Analyses Reveal a Distinct Role of T-Cell Subsets in the Immune Microenvironment of Gastric Cancer. Clinical & Translational Immunology, 9, e1127. [Google Scholar] [CrossRef] [PubMed]
[28] Derks, S., de Klerk, L.K., Xu, X., Fleitas, T., Liu, K.X., Liu, Y., Dietlein, F., Margolis, C., Chiaravalli, A.M., Da Silva, A.C., et al. (2020) Characterizing Diversity in the Tumor-Immune Microenvironment of Distinct Subclasses of Gastroesophageal Adenocarcinomas. Annals of Oncology, 31, 1011-1020. [Google Scholar] [CrossRef] [PubMed]
[29] Cancer Genome Atlas Research Network (2014) Comprehensive Molecular Characterization of Gastric Adenocarcinoma. Nature, 513, 202-209. [Google Scholar] [CrossRef] [PubMed]
[30] Depotte, L., Palle, J., Rasola, C., Broudin, C., Afrăsânie, V.A., Mariani, A. and Zaanan, A. (2023) New Developments and Standard of Care in the Management of Advanced Gastric Cancer. Clinics and Research in Hepatology and Gastroenterology, 48, Article 102245. [Google Scholar] [CrossRef] [PubMed]
[31] Högner, A. and Moehler, M. (2022) Immunotherapy in Gastric Cancer. Current Oncology, 29, 1559-1574. [Google Scholar] [CrossRef] [PubMed]